Exact Sciences Corporation (EXAS) looks stuck. Even after a 244 percent revenue increase on a 260 percent increase in Cologuard tests (to 40,000), the stock is not moving. That might change. Growing commercial insurance coverage will help EXAS’s sales team convince physicians to adopt Cologuard. On its conference call, the company detailed the coverage in the last quarter: "Of those 80 million lives, 46% are covered by Medicare, 46% by Commercial Insurance and 8% by Military and Medicaid programs." Commercial coverage now stands at 25 percent. As the coverage improves, expect orders for Cologuard to pick up. Fully insured people will get coverage for the testing. Reimbursement for regional payers is under negotiations and discussions. For now, markets are not expect much progress. Operationally, EXAS needs strong compliance rates. At 69 percent, it is still too low. The company removed the $50 payment requirement before the kit was shipped. This negatively impacted compliance slightly. Takeaway Markets have low expectations for Exact Sciences. Fundamentals are improving and as uptake for Cologuard grows, EXAS’s share price will recover, too. More biotech reading: Why Bankruptcy is Not Happening for ValeantRelypsa will Survive